Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre
University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on the premises of the University of Oxford. 
CUBE's goal is to push the envelope on innovation. Making change and innovation happen in the industry is a tough challenge that takes knowledge, creativity, time and also courage. No Equity. No obligations. No strings attached. If your startup is outstanding, your products are desperately needed by the industry and the best of all qualifiers, CUBE will give you one million euros in cash. 
Merck, a leading science and technology company, today announced the winners of its Emerging Biotech Grant Program in Europe. Applicants from emerging biotechnology companies across Europe were asked to describe one or more of their current projects, the medical needs they solve and process development challenges they face to be considered for the grant. 
BASF Human Nutrition and Nuritas™ have announced a collaboration that will see the commercialization and discovery of health-benefiting bioactive peptide networks within specific target areas of significant value. Peptides are biologically occurring short chains of amino acids that act as potent signaling molecules in the body. The peptide networks of focus in this collaboration are natural, food-derived, patented and of significant benefit to the health of consumers. 
Novartis announced today that it has entered into a definitive agreement for the acquisition of Ziarco Group Limited, a privately held company focused on the development of novel treatments in dermatology. This acquisition would add a once-daily oral H4 receptor antagonist in development for atopic dermatitis (AD), commonly known as eczema, to complement the growing Novartis dermatology portfolio and pipeline.